Sugi Predict

Sugi Predict / Compounds / SCHEMBL16700299

SCHEMBL16700299

SCHEMBL16700299

CCN(CC)CC.CSc1nc(N)c2ncn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c2n1

nearest known ligand 0.80

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ P2RY1 P47900 6/20 0.80
▸ ENPP1 P22413 4/20 0.80
▸ P2RY12 Q9H244 2/20 0.80
▸ P2RY11 Q96G91 3/20 0.79
▸ P2RX3 P56373 2/20 0.79
▸ P2RX1 P51575 1/20 0.79
▸ P2RY6 Q15077 1/20 0.79
▸ P2RX4 Q99571 1/20 0.79
▸ BLM P54132 2/20 0.73
▸ LMNA P02545 1/20 0.73
▸ KMT2A Q03164 1/20 0.73
▸ NPSR1 Q6W5P4 1/20 0.73
▸ PMP22 Q01453 1/20 0.71
▸ CYP2C19 P33261 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2527383 0.96 P2RY1 (0.86) P2RY1ENPP1P2RY12P2RY11P2RX3
SCHEMBL8862410 0.96 P2RY1 (0.86) P2RY1ENPP1P2RY12P2RY11P2RX3
SCHEMBL3490789 0.96 P2RY1 (0.86) P2RY1ENPP1P2RY12P2RY11P2RX3
SCHEMBL195864 0.89 P2RY1 (1.00) P2RY1ENPP1P2RY12P2RY11P2RX3
SCHEMBL18089710 0.89 P2RY1 (1.00) P2RY1ENPP1P2RY12P2RY11P2RX3
SCHEMBL195865 0.89 P2RY1 (1.00) P2RY1ENPP1P2RY12P2RY11P2RX3
SCHEMBL2463601 0.89 P2RY1 (0.81) P2RY1ENPP1P2RY12P2RY11P2RX3
SCHEMBL12216627 0.89 P2RY1 (0.95) P2RY1ENPP1P2RY12P2RY11P2RX3
SCHEMBL8862431 0.89 P2RX3 (0.81) P2RY1ENPP1P2RY12P2RY11P2RX3
SCHEMBL29381860 0.88 P2RY1 (1.00) P2RY1ENPP1P2RY12P2RY11P2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115418686-B Through hole high-depth copper electroplating solution for glass substrate and copper electroplating process thereof 深圳创智芯联科技股份有限公司 2023-01-10 — — CN disclosed
US-20220411407-A1 ARYL AMINOPYRIMIDINES AS DUAL MERTK AND TYRO3 INHIBITORS AND METHODS THEREOF THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2022-12-29 — — US disclosed
CN-115418686-A Through hole high-depth copper electroplating solution for glass substrate and copper electroplating process thereof 深圳创智芯联科技股份有限公司 2022-12-02 — — CN disclosed
CN-115023417-A Arylaminopyrimidines as dual MERRTK and TYRO3 inhibitors and methods thereof 北卡罗来纳大学教堂山分校 2022-09-06 — — CN disclosed
US-11001586-B2 Alkyl pyrrolopyrimidine analogs and methods of making and using same THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2021-05-11 — — US disclosed
US-20200062764-A1 ALKYL PYRROLOPYRIMIDINE ANALOGS AND METHODS OF MAKING AND USING SAME THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2020-02-27 — — US disclosed
US-10004755-B2 Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2018-06-26 — — US disclosed
US-20170136043-A1 THERAPEUTIC USES OF SELECTED PYRROLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2017-05-18 — — US disclosed
US-9649309-B2 Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2017-05-16 — — US disclosed
US-9603850-B2 MerTK-specific pyrazolopyrimidine compounds THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2017-03-28 — — US disclosed
US-9555031-B2 Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2017-01-31 — — US disclosed
US-9555030-B2 Therapeutic uses of selected pyrazolopyrimidine compounds with anti-Mer tyrosine kinase activity THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2017-01-31 — — US disclosed
US-20150291606-A1 MERTK-SPECIFIC PYRROLOPYRIMIDINE COMPOUNDS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2015-10-15 — — US disclosed
US-20150290212-A1 THERAPEUTIC USES OF SELECTED PYRAZOLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-15 — — US disclosed
US-20150290194-A1 THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-15 — — US disclosed
US-20150290197-A1 THERAPEUTIC USES OF SELECTED PYRROLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-15 — — US disclosed
US-20150291609-A1 MERTK-SPECIFIC PYRIMIDINE COMPOUNDS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2015-10-15 — — US disclosed
US-20150291605-A1 MERTK-SPECIFIC PYRAZOLOPYRIMIDINE COMPOUNDS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-15 — — US disclosed
US-9062392-B2 Methods for isolating a peptide methods for identifying a peptide INTEL CORPORATION (US) 2015-06-23 — — US disclosed
US-20150133305-A1 METHODS FOR ISOLATING A PEPTIDE METHODS FOR IDENTIFYING A PEPTIDE INTEL CORPORATION 2015-05-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150291605-A1 MERTK-SPECIFIC PYRAZOLOPYRIMIDINE COMPOUNDS MERTK, TYRO3, MATK P2RY1 490/4885ENPP1 556/4885P2RY12 766/4885
US-20150290197-A1 THERAPEUTIC USES OF SELECTED PYRROLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY MERTK, FLT3, TK2 P2RY1 2991/4885ENPP1 709/4885P2RY12 3026/4885
US-20150291606-A1 MERTK-SPECIFIC PYRROLOPYRIMIDINE COMPOUNDS MERTK, TYRO3, MATK P2RY1 1028/4885ENPP1 600/4885P2RY12 1042/4885
US-20150290194-A1 THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY MERTK, FLT3, TK1 P2RY1 1243/4885ENPP1 752/4885P2RY12 1339/4885
US-11001586-B2 Alkyl pyrrolopyrimidine analogs and methods of making and using same TYRO3, MERTK, LCK P2RY1 1549/4885ENPP1 654/4885P2RY12 2147/4885
US-20150290212-A1 THERAPEUTIC USES OF SELECTED PYRAZOLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY MERTK, TK1, FLT3 P2RY1 1911/4885ENPP1 840/4885P2RY12 2394/4885
US-20200062764-A1 ALKYL PYRROLOPYRIMIDINE ANALOGS AND METHODS OF MAKING AND USING SAME TYRO3, MERTK, LCK P2RY1 1549/4885ENPP1 654/4885P2RY12 2147/4885
US-20170136043-A1 THERAPEUTIC USES OF SELECTED PYRROLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY MERTK, FLT3, TK2 P2RY1 2991/4885ENPP1 709/4885P2RY12 3026/4885
US-10004755-B2 Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity MERTK, FLT3, TK2 P2RY1 2991/4885ENPP1 709/4885P2RY12 3026/4885
US-20220411407-A1 ARYL AMINOPYRIMIDINES AS DUAL MERTK AND TYRO3 INHIBITORS AND METHODS THEREOF MERTK, TYRO3, MATK P2RY1 566/4885ENPP1 678/4885P2RY12 666/4885
US-20150291609-A1 MERTK-SPECIFIC PYRIMIDINE COMPOUNDS MERTK, TYRO3, MATK P2RY1 324/4885ENPP1 503/4885P2RY12 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.